Drug intelligence / Profile preview

IL-18-secreting CAR T cells

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

IL-18-secreting CAR T cells are an engineered cell therapy designed to treat multiple myeloma, particularly cases with low antigen expression. These chimeric antigen receptor (CAR) T cells are modified to target B-cell maturation antigen (BCMA) and B-cell activating factor receptor (BAFF-R) simultaneously. Additionally, they are engineered to secrete the proinflammatory cytokine interleukin-18 (IL-18). This dual approach aims to overcome the challenge of weak antigen expression on myeloma cells by enhancing T-cell activity, promoting interferon-gamma production, reprogramming the bone marrow microenvironment through type-I/II interferon signaling, and activating macrophages to mediate anti-myeloma activity. The combination of multiantigen targeting and engineered IL-18 secretion has demonstrated the ability to eliminate myeloma with weak antigen expression in preclinical models.

Other names: IL-18-secreting CAR T cellsIL18-secreting CAR T cellsIL 18-secreting CAR T cellsIL-18-secreting CAR-TsIL18-secreting CAR-TsIL 18-secreting CAR-TsIL-18-armored CAR T cellsIL18-armored CAR T cellsIL 18-armored CAR T cells

Targets

BCMA (B-cell maturation antigen)TNFRSF13C (B-cell Activating Factor Receptor)IL-18R (Interleukin-18 receptor complex)

Beyond the preview

Go deeper on IL-18-secreting CAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-18-secreting CAR T cells.

Explore the full profile